Pure Global
NCT05348408

Efficacy of Peri-neural Platelet Rich Plasma Injection in Treatment of Chemotherapy Induced Peripheral Neuropathy.

Efficacy of Ultra-sound Guided Peri-neural Platelet Rich Plasma Injection in Treatment of Chemotherapy Induced Peripheral Neuropathy: Randomized Controlled Trial.
South Egypt Cancer Institute·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chemotherapy-induced Peripheral Neuropathy
Drug/Device/Intervention
platelet rich plasma
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
South Egypt Cancer Institute
Timeline & enrollment
Phase
Phase 2
Start date
Apr 01, 2022
End date
Apr 01, 2024
Enrollment
62 participants
Primary outcome

Change in severity of pain after injection

Summary

This study aims to show the efficacy and safety of ultra-sound guided peri-neural platelet
 rich injection in treatment of chemotherapy induced peripheral neuropathy.

ICD-10 classifications
Drug-induced polyneuropathyParaneoplastic neuromyopathy and neuropathyPolyneuropathy due to other toxic agentsIdiopathic peripheral autonomic neuropathyIdiopathic progressive neuropathy
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05348408
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05348408 through Pure Global AI's free database. This Phase 2 trial is sponsored by South Egypt Cancer Institute and is currently Not yet recruiting. The study focuses on Chemotherapy-induced Peripheral Neuropathy. Target enrollment is 62 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.